Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.36 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16426283 | 1.00 | CHRM1 (0.46) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL1163087 | 0.86 | TDP1 (0.50) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL1300693 | 0.80 | CHRM1 (0.44) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL9323880 | 0.80 | CYP1A2 (0.52) | GRIK1SLC1A3SLC1A2SLC1A1GRIK2 | |
| SCHEMBL28586731 | 0.80 | CHRM1 (0.44) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL12880105 | 0.78 | TDP1 (0.40) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL17037482 | 0.78 | TDP1 (0.40) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL12641501 | 0.76 | CHRM1 (0.39) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL14110749 | 0.75 | TDP1 (0.60) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL5031485 | 0.75 | TDP1 (0.60) | CHRM1AKR1A1CHRM3HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023737-A1 | Imidazo-Pyridazines, Triazolo-Pyridazines and Related Benzodiazepine Receptor Ligands | NEUROGEN CORPORATION (US) | 2009-01-22 | — | — | US | disclosed |
| US-20090023737-A1 | Imidazo-Pyridazines, Triazolo-Pyridazines and Related Benzodiazepine Receptor Ligands | NEUROGEN CORPORATION (US) | 2009-01-22 | — | — | US | disclosed |
| US-20090023737-A1 | Imidazo-Pyridazines, Triazolo-Pyridazines and Related Benzodiazepine Receptor Ligands | NEUROGEN CORPORATION (US) | 2009-01-22 | — | — | US | disclosed |
| EP-1713784-A1 | IMIDAZO-PYRIDAZINES, TRIAZOLO-PYRIDAZINES AND RELATED BENZODIAZEPINE RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2006-10-25 | — | — | EP | disclosed |
| US-7122546-B2 | Imidazol-1-ylmethyl pyridazine derivatives | NEUROGEN CORPORATION (US) | 2006-10-17 | — | — | US | disclosed |
| WO-2005080355-A1 | IMIDAZO-PYRIDAZINES, TRIAZOLO-PYRIDAZINES AND RELATED BENZODIAZEPINE RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2005-09-01 | — | — | WO | disclosed |
| WO-2005080355-A1 | IMIDAZO-PYRIDAZINES, TRIAZOLO-PYRIDAZINES AND RELATED BENZODIAZEPINE RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2005-09-01 | — | — | WO | disclosed |
| EP-1549636-A1 | IMIDAZOL-1-YLMETHYL PYRIDAZINE DERIVATIVES | Neurogen Corporation (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040077653-A1 | Imidazol-1-ylmethyl pyridazine derivatives | NEUROGEN CORPORATION | 2004-04-22 | — | — | US | disclosed |
| WO-2004031174-A1 | IMIDAZOL-1-YLMETHYL PYRIDAZINE DERIVATIVES | NEUROGEN CORPORATION (US) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023737-A1 | Imidazo-Pyridazines, Triazolo-Pyridazines and Related Benzodiazepine Receptor Ligands | GABRA4, GABRA2, GABRA5 | CHRM1 50/4885AKR1A1 998/4885CHRM3 122/4885 |
| US-20040077653-A1 | Imidazol-1-ylmethyl pyridazine derivatives | GABRA5, GABRA1, GABRA2 | CHRM1 152/4885AKR1A1 538/4885CHRM3 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.